UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

\mathbf{T}	T 3 F	0 T/
	RM	K
ГО		U-17

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2012

Commission File Number: 001-34563

CONCORD MEDICAL SERVICES HOLDINGS LIMITED

18/F, Tower A, Global Trade Center
36 North Third Ring Road East, Dongcheng District
Beijing 100013
People's Republic of China

People's Republic of China (Address of principal executive offices)	
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.	
Form 20-F ⊠ Form 40-F □	
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \Box	
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \Box	
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Compursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.	mission
Yes □ No ⊠	
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): N/A	

TABLE OF CONTENTS

SIGNATURE EX-99.1 EX-99.2

TABLE OF CONTENTS

Exhibit 99.1 – Press release: Concord Medical Announces Acquisition of Controlling Equity Interest in Chang'an Hospital Exhibit 99.2 – Press release: Concord Medical Reports Fourth Quarter and Full Year 2011 Financial Results

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CONCORD MEDICAL SERVICES HOLDINGS LIMITED

By: /s/ Jianyu Yang

Name: Jianyu Yang

Title: Director, Chief Executive Officer and President

Date: March 22, 2012

Concord Medical Announces Acquisition of Controlling Equity Interest in Chang'an Hospital

BEIJING, March 21, 2012 — Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading hospital management company and the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced the signing of a purchase agreement under which the Company agreed to acquire 52% of the equity interest of Chang'an Hospital in a cash transaction for approximately RMB248 million (\$39.4 million). Chang'an Hospital is one of the largest private-owned general hospitals in China, located in Xi'an City, Shaanxi Province, China.

"We are very pleased to welcome Chang'an Hospital to the CCM family," Dr. Jianyu Yang, Chairman and CEO said. "As a private hospital with over 10 years of operating history, Chang'an Hospital has now entered into the stage of profitable growth. After the completion of the acquisition, Chang'an Hospital will be integrated into CCM's nationwide network. In the future, we plan to establish strategic alliances with leading medical institutions in the world, to improve the medical service quality and management efficiency of Chang'an Hospital. This acquisition is the important first step towards transforming CCM into a leader in China's healthcare service sector."

Chang'an Hospital, with over 1,000 beds, is one of the largest privately-owned general hospitals in China. Combined with CCM's 131 radiotherapy and diagnostic imaging centers located across China, Chang'an Hospital will serve as the regional hub in CCM's nationwide network and cover the northwestern region of China, which has over 100 million population. Upon completion of the acquisition, CCM will become one of the few US-listed companies to own a controlling equity interest in a private general hospital in China.

"The acquisition of Chang'an Hospital is an important milestone in CCM's development," Dr. Yang commented. "This transaction will enable us to accumulate important hospital operating experience and management techniques, strengthen our own medical and hospital management team, and prepare for the planned opening of other specialty hospitals in the CCM network. Our long-term strategy is to become the leading hospital management and operating company in China."

Since 2009, CCM has worked with Chang'an Hospital as part of its equipment lease and management business. In 2010, CCM and Chang'an Hospital jointly established CCICC, a specialty oncology hospital, which will be merged into Chang'an Hospital after the closing of this transaction.

The transaction has been approved by the boards of directors of both CCM and Chang'an Hospital and is expected to close in the second quarter or the beginning of the third quarter of calendar 2012, subject to certain closing conditions and government approvals. The acquisition is expected to be accretive to CCM earnings per share beginning at the third quarter of 2012.

About Concord Medical

Concord Medical Services Holdings Limited operates the largest network of radiotherapy and diagnostic imaging centers in China, measured by revenues and the number of centers in operation. As of December 31, 2011, the Company operated a network of 131 centers with 73 hospital partners that spanned 51 cities and 24 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, Concord Medical provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients. For more information, please see http://ir.concordmedical.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, many of the statements from management in this press release and the section under "Outlook for Full Year 2012" are forward-looking in nature. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Such factors include: the number of new radiotherapy and diagnostic imaging centers opened; the increase in the number of patients in existing centers; the establishment of specialty cancer hospitals; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government; and technological or therapeutic changes affecting the field of cancer treatment and diagnostic imaging. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Statement Regarding Unaudited Financial Information

The Company's independent auditors are in the process of completing an audit of the Company's U.S. GAAP financial statements for 2011. These unaudited 2011 numbers disclosed in this announcement are, therefore, subject to change.

For more information, please contact:

Concord Medical Services

Mr. Tony Tian tony.tian@concordmedical.com (+86) 10 5957-5287

Solebury Communications

In China: Ms. Cindy Li cli@soleburyir.com (+86) 10 6563-0288

In the United States Mr. Richard Zubek rzubek@soleburyir.com (+1) 203-428-3230

Concord Medical Reports Fourth Quarter and Full Year 2011 Financial Results

BEIJING, March 21, 2012 — Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a leading hospital management company and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced its unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2011¹.

Fourth Quarter Highlights

- Total net revenues increased by 1.1% to RMB114.1 million (\$18.1 million), compared to the fourth quarter of 2010.
- Net loss was RMB310.0 million (\$49.3 million), primarily due to a goodwill impairment charge of RMB300.2 million (\$47.7 million) and one-time bad debt and other provisions of RMB49.1 million (\$7.8 million). Non-GAAP net income² was RMB41.7 million (\$6.6 million), a 13.2% decrease from the fourth quarter of 2010.
- Basic and diluted net loss per American Depositary Share ("ADS")³ was RMB6.56 (\$1.04), compared to basic and diluted net income per ADS RMB0.87 in the fourth quarter of 2010. Non-GAAP basic and diluted earnings per ADS were RMB0.87 (\$0.14) compared to non-GAAP basic and diluted earnings per ADS of RMB0.96 in the fourth quarter of 2010.
- Concord Medical opened four centers in the fourth quarter of 2011, bringing the total number of centers in operation to 131 across 51 cities in China, as of December 31, 2011.
- The total numbers of treatment and diagnostic patient cases were 9,052 and 43,374, respectively, representing 8.9% and 25.2% increases from the fourth quarter of 2010, respectively.

Full Year 2011 Highlights

- Total net revenues were RMB450.1 million (\$71.5 million), a 15.6% increase from 2010.
- Gross profit was RMB290.7 million (\$46.2 million), a 9% increase from 2010.
- Net loss was RMB211.4 million (\$33.6 million), primarily due to a goodwill impairment charge of RMB300.2 million (\$47.7 million) and bad debt and other provisions of RMB49.3 million (\$7.8 million). Non-GAAP net income was RMB147.3 million (\$23.4 million), a 3.0% increase from 2010.
- Basic and diluted net loss per ADS was RMB4.53 (\$0.72); Non-GAAP basic and diluted earnings per ADS were RMB3.03 (\$0.48), a 4.1% increase from RMB2.91 in 2010.
- The total numbers of treatment and diagnostic patient cases were 34,388 and 166,516, respectively, representing 7.7% and 28.0% increases from 2010, respectively.

This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB6.2939 to US\$1.00, the effective noon buying rate as of December 31, 2011 in the City of New York for cable transfers of RMB as certified for customs purposes by the Federal Reserve Bank of New York.

Non-GAAP net income is defined in this announcement as net income excluding share-based compensation, the impact of goodwill impairment, bad debt provision and other adjustments. Share-based compensation was RMB 2.4 million (\$0.4 million) in the fourth quarter of 2011 and RMB9.2 million (\$1.5 million for the full year 2011. Goodwill impairment charges in the fourth quarter totaled RMB 300.2 million (\$47.7 million), and bad debt provision and other impairment charges were RMB49.1 million (\$7.8 million).

Each ADS represents three ordinary shares of the Company.

"2011 was a transformational year for Concord Medical as we built a solid foundation for CCM to become a leader in China's healthcare service sector," said Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical. "We focused on improving our operational efficiencies, while also increased the number of centers in our network and delivered positive financial results. Our revenue in 2011 grew by 15.6% compared with 2010 and we added 13 new centers, bringing the total number of centers in our network to 131 at the year end. The CCM network now covers 51 cities in 24 provinces in China. We are now seeing a more balanced revenue contribution, both geographically and operationally from our radiotherapy and diagnostic lines. In addition, we believe our new contract pipeline will provide stable revenue growth from our centers in 2012. We have adopted a rigorous and balanced decision-making process for investments in new centers in order to enhance our return on capital.

"The government continues to encourage private investment into the healthcare system in China," continued Dr. Yang. "In December 2011, the newly issued Foreign Investment Catalogue 2011 revision moved the healthcare service sector to 'permitted' from 'restricted' category. Leveraging this more favorable policy environment and our effective marketing and execution efforts, we are confident that Concord Medical will capitalize on the opportunity and achieve our goal to become a leader in China's healthcare services industry."

2011 Fourth Quarter Results

Total net revenues were RMB114.1 million (\$18.1 million), representing a 1.1% increase from the fourth quarter of 2010. The flat revenue growth was due to the Company's decision to not recognize service revenue from the Chang'an Hospital due to the ongoing acquisition of the controlling equity interests in Chang'an Hospital.

Cost of revenues was RMB44.8 million (\$7.1 million), representing a 42.9% increase from the fourth quarter of 2010, mainly due to the increased consumables expenses, selling and medical promotional expenses at the center level, and the increased usage of disposable medical supplies.

Gross margin decreased to 60.8% from 66.5% in the third quarter of 2011 and 72.2% in the fourth quarter of 2010, primarily due to the increased cost of revenues and relatively flat revenue growth.

Operating expenses, consisting of selling expenses and general and administrative expenses, were RMB78.3 million (\$12.4 million) in the fourth quarter of 2011 as compared to RMB25.0 million in the third quarter of 2011 and RMB30.1 million in the fourth quarter of 2010. The increase was primarily due to the company's decision to take one-time bad debt provision and other impairment charges, totaling RMB49.1 million, due to uncertainty in connection with the collectability of certain equipment deposits and outstanding receivables. The charge will be reversed at collection or installation of the related equipment.

Operating loss was RMB8.9 million (\$1.4 million), compared to operating income of RMB51.4 million in the fourth quarter of 2010. The loss was mainly due to bad debt provision and other impairment charges incurred during the quarter.

Goodwill impairment charges

A substantial portion of goodwill on the Company's balance sheet relates to the acquisitions by the Company's predecessor before the Company's IPO in December 2009. During the year of 2011, the market circumstances prompted management to evaluate and test the fair value of the Company's assets against their carrying amount in accordance with U.S. GAAP. Based on the testing, the Company concluded that the implied goodwill is insufficient to cover the carrying amount of goodwill and consequently recorded a goodwill impairment charge of RMB 300.2 million (\$47.7 million) during the fourth quarter of 2011.

The charge is a non-cash item and will not affect the Company's cash flows, liquidity position or borrowing capacity under its credit facilities; and is excluded from the Company's financial results in evaluating financial covenants under its credit agreements.

Net loss was RMB310.0 million (\$49.3 million) as a result of the above, compared to net income of RMB43.7 million in the fourth quarter of 2010. **Both basic and diluted losses per ADS** in the fourth quarter of 2011 amounted to RMB6.56 (\$1.04), compared to basic and diluted earnings per ADS of RMB 0.87 in the fourth quarter of 2010.

Non-GAAP net income was RMB41.7 million (\$6.6 million), compared to non-GAAP net income of RMB48.0 million in the fourth quarter of 2010. **Both non-GAAP basic and diluted earnings per ADS in** the fourth quarter of 2011 were RMB0.87 (\$0.14), compared to non-GAAP basic and diluted earnings per ADS of RMB 0.96 in the fourth quarter of 2010.

Adjusted EBITDA4 (non-GAAP) was RMB74.8 million (\$11.9 million) in the fourth quarter of 2011.

Share-based compensation expenses, which were allocated to related operating expense items, were RMB2.4 million (\$0.4 million) in the fourth quarter of 2011, compared to RMB1.8 million in the fourth quarter of 2010.

Income tax expense in the fourth quarter of 2011 was RMB6.8 million (\$1.1 million), compared to RMB10.1 million in the fourth quarter of 2010.

Fiscal 2011 Full Year Results

Total net revenues were RMB450.1 million (\$71.5 million), a 15.6% increase from RMB389.5 million in 2010.

Cost of revenues in 2011 was RMB159.4 million (\$25.3 million), representing a 29.9% increase from RMB122.7 million in 2010. The increase was primarily due to increases in consumables expenses, selling and medical promotional expenses, and usage of disposable medical supplies.

Gross profit margin in 2011 was 64.6%, compared to 68.5% in 2010, primarily due to the increased cost of revenues and relatively flat revenue growth.

Selling expenses in 2011 were RMB37.5 million (\$6.0 million), compared to RMB17.2 million in 2010. Selling expenses as a percentage of total net revenues increased to 8.3% in 2011 from 4.4% in 2010. The increase was primarily due to rising sales and marketing efforts and other expenses to support business expansion.

⁴ Adjusted EBITDA is defined in this announcement as net (loss) income plus interest, taxes, depreciation and amortization, share-based compensation expenses, goodwill impairment charge, bad debt provision and other adjustments. Other adjustments include foreign exchange loss and other income.

General and administrative expenses in 2011 were RMB114.4 million (\$18.2 million), including a bad debt provision of RMB15.5 million and other impairment charge of RMB33.8 million.

Goodwill impairment charge in 2011 was RMB300.2 million (\$47.7 million).

Operating income was RMB138.9 million (\$22.1 million), compared to RMB179.7 million in 2010.

Net loss in 2011 was RMB211.4 million (\$33.6 million), compared to net income of RMB130.9 million in 2010. Both basic and diluted losses per ADS for 2011 were RMB4.53 (\$0.72).

Non-GAAP net income for 2011 was RMB147.3 million (\$23.4 million), compared to RMB143.0 million in 2010. Both non-GAAP basic and diluted earnings per ADS in 2011 were RMB3.03 (\$0.48), compared to RMB2.91 in 2010.

Adjusted EBITDA (non-GAAP) was RMB318.4 million (\$50.6 million) in 2011, compared to RMB297.9 million in 2010.

Share-based compensation expenses, which were allocated to related operating expense items, were RMB9.2 million (\$1.5 million) in 2011, compared to RMB9.6 million in 2010.

Income tax expense in 2011 was RMB46.3 million (\$7.4 million), compared to an income tax expense of RMB43.9 million in 2010.

As of December 31, 2011, the Company had **total fixed assets** valued at RMB1,068.7 million (\$169.8 million), **cash and cash equivalents** of RMB219.1 million (\$34.8 million), restricted cash of RMB24.5 million (\$3.9 million), held-to-maturity securities of RMB100.5 million (\$16.0 million) and time deposit of RMB50.4 million (\$8.0 million), totaling RMB394.5 million (\$62.7 million).

Capital expenditures were RMB339.9 million (\$54.0 million) in 2011, compared to RMB345.2 million in 2010. The Capital expenditures were primarily for equipment deposits for new centers.

As of December 31, 2011, the Company had **bank credit lines** in the aggregate amount of RMB565.0 million (\$89.8 million), of which RMB185.6 million (\$29.5 million) was utilized.

Accounts receivable was RMB244.2 million (\$38.8 million) as of December 31, 2011, compared to RMB242.8 million as of September 30, 2011 and RMB169.4 million as of December 31, 2010. Days sales outstanding (DSO) was approximately 192 days in the fourth quarter of 2011, up from 170 days in the third quarter of 2011 and 127 days in the fourth quarter of 2010. The increase was mainly due to accounts receivables related to Chang'an Hospital. The management expects DSO to revert to lower level in 2012, after the closing of Chang'an Hospital acquisition.

During the fourth quarter of 2011, the Company repurchased 316,645 ADSs, representing 949,935 ordinary shares, for an aggregate consideration of \$1.1 million, including commissions. As of December 31, 2011, the Company had total 47.4 million outstanding ADSs.

Recent Developments

On March 21, 2012, the Company announced the signing of a purchase agreement under which the Company agreed to acquire 52% of the equity interests in Chang'an Hospital for a consideration of RMB248 million in cash. Chang'an Hospital has over 1,000 patient beds, and is one of the largest privately-owned general hospitals in China, located in Xi'an City, Shaanxi Province, China. The transaction has been approved by the boards of directors of both Concord Medical and Chang'an Hospital and is expected to close in the first half of 2012, subject to certain closing conditions and relevant government approvals.

"The acquisition of Chang'an Hospital is an important milestone in CCM's development," Dr. Yang commented. "We have been partners with Chang'an Hospital since 2009, and in 2010 we jointly founded CCICC, a specialty oncology hospital. We are excited about this transaction and its positive impact on CCM's overall strategy of becoming the leading hospital and management operating company in China."

The Company also announced that the board of directors has appointed Mr. Adam Jigang Sun as the Chief Financial Officer. Mr. Sun has served as the Acting CFO of the Company since September 2011.

2012 Outlook

The Company expects to consolidate the financial results of Chang'an Hospital beginning at the third quarter of 2012. Based on current market and operating conditions, estimated business expansion and forecasted Chang'an Hospital financial results, the company provides the following financial guidance for the 2012 fiscal year:

- Total net revenues of RMB590 million to RMB630 million, or 30%-40% year-over-year growth;
- growth in total net revenues of lease and management service of 15% to 18%;
- revenue from Chang'an Hospital of RMB190 million to RMB210 million, reflecting consolidation of 6-months financial results; and
- capital expenditures of RMB250 million to RMB275 million.

The company is targeting to obtain the license of at least one specialty oncology hospital in 2012.

The foregoing reflects Concord Medical's current and preliminary views, which are subject to change.

Conference Call Information

Concord Medical's management will hold an earnings conference call at 8:00 a.m. Eastern Time on March 22, 2011 (8:00 p.m. Beijing/Hong Kong time on March 22, 2011).

Dial-in details for the earnings conference call are as follows:

U.S. Toll Free: 1-866-519-4004 International: 1-718-354-1231 U.K. Toll Free: 8082346646

China Toll Free: 400-620-8038 / 800-819-0121

Hong Kong Toll Free: 800-930-346 Passcode: CCM

A replay of the conference call may be accessed by phone at the following number until March 29, 2011:

U.S. Toll Free: 1-866-214-5335 International: 1-718-354-1232 Passcode: 58954479 Additionally, a live and archived webcast of this conference call will be available at http://ir.concordmedical.com/.

About Concord Medical

Concord Medical Services Holdings Limited operates the largest network of radiotherapy and diagnostic imaging centers in China, measured by revenues and the number of centers in operation. As of December 31, 2011, the Company operated a network of 131 centers with 73 hospital partners that spanned 51 cities and 24 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, Concord Medical provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients. For more information, please see http://ir.concordmedical.com/.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "should" and "will" and similar expressions. In particular, many of the statements from management in this press release and the section under "Outlook for Full Year 2012" are forward-looking in nature. These forward looking statements are based upon management's current views and expectations with respect to future events and are not a guarantee of future performance. Furthermore, these statements are, by their nature, subject to a number of risks and uncertainties that could cause actual performance and results to differ materially from those discussed in the forward-looking statements as a result of a number of factors. Such factors include: the number of new radiotherapy and diagnostic imaging centers opened; the increase in the number of patients in existing centers; the establishment of specialty cancer hospitals; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government; and technological or therapeutic changes affecting the field of cancer treatment and diagnostic imaging. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Statement Regarding Unaudited Financial Information

The Company's independent auditors are in the process of completing an audit of the Company's U.S. GAAP financial statements for 2011. These unaudited 2011 numbers disclosed in this announcement are, therefore, subject to change.

About Non-GAAP Financial Measures

To supplement the consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles (GAAP), Concord Medical uses certain non-GAAP measures. The Company presents certain of its financial information that is adjusted from results based on GAAP to exclude the impact of share-based compensation expense, bad debt provision and goodwill impairment loss. The Company believes excluding share-based compensation expense, bad debt provision and goodwill impairment loss from its GAAP financial measures is useful for its management and investors to assess and analyze the Company's core operating results as such expenses are not directly attributable to the underlying performance of the Company's business operations and do not impact its cash earnings. Concord Medical also believes these non-GAAP measures excluding share-based compensation expense, bad debt provision and goodwill impairment loss are important in helping investors to understand the Company's current financial performance and future prospects and to compare business trends among different reporting periods on a consistent basis. In addition, Concord Medical also presents the non-GAAP measure of Adjusted EBITDA, which is defined in this announcement as net (loss) income plus interest, taxes, depreciation and amortization, share-based compensation expenses, bad debt provision, goodwill impairment and other adjustments. Other adjustments include foreign exchange loss, gain from disposal of equipment and other income or expenses. Furthermore, Adjusted EBITDA eliminates the impact of items that the Company does not consider indicative of the performance of its network of centers. The Company believes investors will similarly use Adjusted EBITDA as one of the key metrics to evaluate its financial performance and to compare its current operating results with corresponding historical periods and with other companies in the healthcare services industry. The presentation of these additional measures should not be consi

For more information, please contact:

Concord Medical Services

Mr. Tony Tian tony.tian@concordmedical.com (+86) 10 5957-5287

Solebury Communications

In China: Ms. Cindy Li cli@soleburyir.com (+86) 10 6563-0288

In the United States: Mr. Richard Zubek rzubek@soleburyir.com (+1) 203-428-3230

Concord Medical Services Holdings Co., Ltd. Unaudited Condensed Consolidated Balance Sheets (in thousands)

Name		As of December 31, 2010 (*)	As of Decer 201	
Current asset 55,788 219,078 3.8 a.8 a.8 a.8 a.9				
	ASSETS			
### Part				
Held-showarity				
Time Deposit の	•	102,873		
Notes recivable 900 ————————————————————————————————————		-		
Accounts revivable 169,80 24,10 30,90 Perpayments on the current asses 74,40 61,60 70,20 Net mixes the inflancing lesses, current portion 19,48 40,82 71,65 Deferred tax asses, current portion 904,41 75,89 88 Total current assets 904,41 73,80 16,86 Property, plant and equipment, net 907,33 10,68,70 20,80 Cooked 161,11 220,00 20,90 30,80 Deposits for non-current assets 90,22 10,90 30,90 <			50,372	8,003
Popp parties and other current parties 74,469 4,61,50 79,20 Net investments in financing lesses, current portion 15,04 5,50 8,06 Total current assets 904,16 25,05 18,06 Non-current assets 904,16 25,00 18,06 Non-current assets 907,33 1,06,00 10 Coping of integral and equipmen, net 16,11 20,00 20 Acquired intangille assets, net 126,10 20,00 13,00 20 Deposits for non-current portion 6,635 9,20 15,30 3 35,30				
Net investments in financing leases, current portion 19,48 48,28 7.916 Ceferred was sels, current portion 10.00 7.30.00 18,00 Concurrent assets 904,41 7.30.00 18,00 Convention and equipment, net 907,33 1,06,00 30,00 Experint plant and equipment, net 907,30 1,06,00 30,00 Convention 61,61 1,29,00 30,00 Experint plant and equipment, net 90,00 30,00 30,00 Convention 61,00 30,00 30,00 30,00 Perpention and the seases, non-current portion 61,00 9,00 1,13,00 30,00 30,10 30,00 30,10 30,00 30,10 30,00 30,10 30,00 30,10 30,00				
Defend clarcases 9.04.01 5.5.09 8.88 Total current assets 904.416 73.567 16.566 Non-current assets 907.303 10.80,000 10.80,0				
Total current assets 904,416 733,657 16,566 Non-current assets 907,333 1,068,70 10,000 Condwill 907,333 1,068,70 10,000 Condwill 300,13 -0 -0 Acquired tanaghle assets, net 14,113 20,935 23,935 Net investments infinancing leases, non-current portion 65,366 70,262 13,535 Deferred assets, non-current portion 16,166 70,272 13,535 Other non-current assets 15,667 70,272 13,536 Description of assets, non-current portion 15,167 70,272 13,536 Restricted cash, non-current portion 15,168 70,272 13,536 Prepaid land lease payments 15,108 73,509 23,318 Total non-current assets 15,108 73,309 23,318 Total and current assets 15,108 23,336 23,318 Total and potential sease, pursue portion 83,000 15,000 23,336 Langestern bank borrowings 25,000 25,000 23,300				
Non-curred assets 907,336 1,068,703 10,080,700 Groodwill 300,105 1,068,703 1,068,703 1,068,703 1,068,703 1,068,703 1,068,703 1,068,703 1,068,703 1,068,703 1,068,703 1,068,703 2,029,000 2,048,000 2,049,000 2,049,000 2,048,000 2,048,000 2,048,000 2,048,000 2,048,000 2,048,000 2,048,000 3	-			
Property, Jant and equipment, net 907,336 108,000 Goodwill 30.63 — Acquired intangible assets, net 146,113 129,018 20,499 Deposits for non-current assets 222,019 207,287 32,935 Defered tax assets, non-current portion 21,869 20,866 3,315 Other non-current assets 14,792 22,012 3,497 Prepaid land lease payments 28,113 27,072 4,349 Prepaid land lease payments 28,103 26,304 23,346 Total non-current sests 1,758,628 1659,789 26,311 Total son-current assets 2,663,04 2,93,40 38,00 Ital List 2,663,04 2,93,40 2,93,40 Ital List 2,663,04 2,93,40 2,93,40 <tr< td=""><td>Total current assets</td><td>904,416</td><td>733,657</td><td>116,566</td></tr<>	Total current assets	904,416	733,657	116,566
Goodwill 300,163 — Acquired intangible assets, net 146,13 20,98 20,98 Deposis for non-current assets 222,019 20,78 32,935 Net investments in financing leases, non-current portion 66,35 97,262 15,433 Ober non-current assets 51,867 87,271 13,666 Restricted cash, non-current portion 28,13 27,370 43,48 Prepaid land lease payments 28,11 27,370 43,48 Prepaid land lease payments 28,13 27,370 43,48 Total asset 1,758,628 150,788 28,71 Total asset 2,663,04 23,30 28,70 Total asset 83,000 15,000 23,83 Lot BLITITES 83,000 15,000 23,33 Dorita Carrent Liabilities 83,000 15,000 32,30 <td>Non-current assets</td> <td></td> <td></td> <td></td>	Non-current assets			
Acquired intangible assets, net 146,113 129,018 20,499 Deposits for non-current assets 222,019 207,287 32,935 Deposits for non-current assets 66,356 97,207 15,953 Defended the assets, non-current portion 21,869 20,866 3,315 Other non-current assets 51,867 87,271 13,066 Restricted cash, non-current portion 28,113 27,370 4,349 Prepaid land lease payments 28,113 27,370 4,349 Total an-current assets 26,63,44 23,346 30,806 Total an-current assets 26,63,44 23,346 30,806 Total assets 2,663,44 23,346 30,806 Charrent assets 83,000 15,000 2,83 Long-term bank borrowings 83,000 15,000 2,83 Long-term bank borrowings, current portion 69,96 77,479 12,31 Accrual for purchase of property, plant and equipment 10,404 13,294 2,112 Dibigations under capital lesses, current portion 49,935	Property, plant and equipment, net	907,336	1,068,703	169,800
Deposits for non-current assers 22,01 20,78 3.20,55 Net nivestments in financing leases, non-current portion 66,35 97,26 15,43 Deferred tax assets, non-current portion 21,68 20,68 3,15 Other non-current assets 14,79 20,12 3,40 Restricted cask, non-current portion 21,75 4,34 2,30 4,34 Pread land lease payments 1,75,86 16,59,789 36,31 2,00 2,00 3,34 30,00 2	Goodwill	300,163	_	_
Deposits for non-current assers 22,01 20,78 3.20,55 Net nivestments in financing leases, non-current portion 66,35 97,26 15,43 Deferred tax assets, non-current portion 21,68 20,68 3,15 Other non-current assets 14,79 20,12 3,40 Restricted cask, non-current portion 21,75 4,34 2,30 4,34 Pread land lease payments 1,75,86 16,59,789 36,31 2,00 2,00 3,34 30,00 2	Acquired intangible assets net	146 113	129 018	20 499
Net investments in financing leases, non-current portion 6,56 9,726 15,43 Defere dax assets, non-current portion 21,869 20,866 3,315 Other non-current assets 15,667 87,271 13,666 Restricted ash, non-current portion 26,131 27,370 43,49 Total assets 1,556,68 1,659,789 26,314 Total assets 2,663,40 1,559,68 1,509,789 Itabilities 83,00 15,000 2,338 LABLITIES AND EQUITY 83,000 77,479 12,310 LABLITIES AND EQUITY 83,000 77,479 12,310 LABLITIES AND EQUITY 83,000 77,479 12,310 Accought in purple soft poperty purple of the post of poperty purple of the pur			,	
Deference ax sases, non-current portion 21,869 20,866 3,315 Other non-current assets 51,867 87,271 1,366 Restricted cash, non-current portion 24,179 22,012 3,439 Pregal land lease payments 1,758,628 1,559,789 63,714 Total assets 1,758,628 1,559,789 63,714 Total assets 2,663,044 2,33,346 30,808 LABLITIES AND EQUITY Current Isabilities Standard Botrowings 83,000 15,000 2,33 Cocyan pack borrowings, current portion 9,032 2,77 3,21 Accual for purchase of property, plant and equipment 10,302 7,77 12,31 Accual for purchase of property, plant and equipment 19,004 13,29 1,11 Obligations under capital leases, current portion 3,582 59,09 9,30 Accured expenses and other liabilities 49,935 59,09 9,30 Incerted tax bayable 2,541 2,003 3,26 Deferered tax ibabilities 2,542<			- / -	
Other non-current assets 5,1867 8,7271 13,866 Restricted cash, non-current portion 14,792 22,012 3,497 Prepaid land lease payments 28,113 27,370 4,348 Total ansets 1,586,88 155,978 28,714 Itable States 2,680,40 2,393,40 3,808 LABILITIES AND EQUITY 2 2 3,800 15,000 2,833 Long-term bank borrowings 83,000 15,000 2,833 Long-term bank borrowings, current portion 60,906 77,479 12,310 Accoul for purplase of property, plant and equipment 10,004 13,294 2,112 Obligations under capital leases, current portion 3,532 5,907 9,309 Income tax payable 25,007 2,909 1,900 3,326 2,509 9,309 Income lax payable 25,007 2,909 2,909 1,900 1,906 2,909 1,909 1,906 2,902 1,907 2,909 1,909 1,906 2,002 1,908 2,906 <t< td=""><td></td><td></td><td></td><td></td></t<>				
Restricted ash, non-current portion 14,792 22,012 3,497 Prepail and lease payments 28,13 27,370 4,34 Total annecurent assets 1,578,668 1,589,678 26,714 Total assets 26,604 2,334 28,008 LABLITIES AND EQUITY Experim labilities 83,000 15,000 2,383 Long-tem bank borrowings 83,000 15,000 2,383 Long-tem bank borrowings, current portion 60,000 77,79 1,310 Accounts payable 10,004 13,224 2,112 Obligations under capital leases, current portion 49,035 59,07 9,30 Cercued expense and other liabilities 49,035 19,09 9,30 Concurrent Rabilities 49,035 19,09 19,00 Cefered revenue, current portion 11,50 11,50 10,00 Cefered revenue, current portion 9,00 16,00 10,00 Total current liabilities 2,00 1,00 1,00 1,00 Ceferent bank borrowings, no				
Prepaid land lease payments 28,113 73,70 4,348 Total assets 1,758,628 1,659,789 26,714 Total assets 2,663,04 2,333,46 28,020 LARBILITIES AND EQUITY Userent liabilities Short-em bank borrowings, current portion 60,096 7,779 2,333 Accous long-term bank borrowings, current portion 10,332 2,172 3,45 Accoula for purchase of property, plant and equipment 10,404 3,204 2,132 Accoula for purchase and other liabilities 3,502 3,502 3,502 Accoula for purchase and other liabilities 49,935 5,907 9,303 Accoula for purchase and other liabilities 45,935 5,907 9,302 Accoula for purchase and other liabilities 45,007 1,315 2,002 3,302 Defended revenue, current portion 45,007 1,315 2,002 3,302 3,302 1,002 1,002 1,002 1,002 1,002 1,002 1,002 1,002 1,002 1,002 1,002 <				
Total non-current assets 1,758,628 1,659,789 263,744 Total assets 2,663,04 2,633,46 2,832,80 LIABILITIES AUD EQUITY User titabilities Short cam bank borrowings 83,000 15,000 2,333 Long-tern bank borrowings, current portion 60,906 77,479 12,315 Accounts payable 10,104 13,224 2,112 Accupil for purchase of property, plant and equipment 10,404 13,294 2,12 Obligations under capital leases, current portion 35,82 59,007 9,300 Crucude expenses and other liabilities 25,401 20,935 3,206 Obligations under capital leases, current portion 11,520 31,115 2,002 Deferred revenue, current portion 11,520 31,115 2,002 Contract payable 49,935 59,007 9,300 Deferred revenue, current portion 11,520 31,115 2,002 Contract Liabilities 45,009 10,709 12,712 Deferred revenue, current portion 9,102<	, 1			
Total assers 2,683,44 2,933,46 308,08 LABILITIES AND EQUITY Corner Itabilities 83,00 15,00 2,383 Short-rem bash borrowings 83,00 15,00 2,383 Corner Inspiration 60,906 77,47 12,10 Accounts payable 10,33 2,10 3,52 15,20 Occupit on purchase of property, plant and equipment 3,58 3,582 5,00 2,01 Occupit on purchase of property, plant and equipment 3,582 3,502 5,00 2,01 Occupit on purchase of property, plant and equipment 3,582 3,502 5,00 2,01 3,02 5,00 2,01 3,02 5,00 3,02 5,00 2,00 3,00				
Carrent liabilities				
Current liabilities 83,000 15,00 2,83 Short-tem bank borrowings 83,000 15,00 2,83 Long-term bank borrowings, current portion 60,906 77,479 12,310 Accounts payable 10,332 2,170 345 Accrual for purchase of property, plant and equipment 3,582 3582 569 Accrual for purchase of property, plant and equipment 3,582 3582 569 Accrual for purchase of property, plant and equipment 3,582 3582 569 Accrual for purchase of property, plant and equipment 3,582 3,582 569 Accrual for purchase of property, plant and equipment 3,582 3,582 569 Accrual for purchase of property, plant and equipment 3,582 3,582 569 39.00 Income tax payable 2,593 3,582	Total assets	2,003,044	2,333,440	300,200
Current liabilities 83,000 15,00 2,83 Short-tem bank borrowings 83,000 15,00 2,83 Long-term bank borrowings, current portion 60,906 77,479 12,310 Accounts payable 10,332 2,170 345 Accrual for purchase of property, plant and equipment 3,582 3582 569 Accrual for purchase of property, plant and equipment 3,582 3582 569 Accrual for purchase of property, plant and equipment 3,582 3582 569 Accrual for purchase of property, plant and equipment 3,582 3,582 569 Accrual for purchase of property, plant and equipment 3,582 3,582 569 Accrual for purchase of property, plant and equipment 3,582 3,582 569 39.00 Income tax payable 2,593 3,582	LIABILITIES AND EQUITY			
Long-term bank borrowings, current portion 60,006 77,479 12,310 Accounts payable 10,332 2,170 345 Accrual for purchase of property, plant and equipment 10,404 13,294 2,112 Obligations under capital leases, current portion 3,582 3,582 569 Accrued expenses and other liabilities 49,935 59,097 9,306 Income tax payable 25,401 20,966 3,326 Deferred revenue, current portion 11,520 13,115 2,084 Contingent business acquisition consideration 14,072 11,999 1,906 Chatle current liabilities 269,152 216,279 3,426 Total current liabilities 9,081 6,839 1,087 Deferred revenue, non-current portion 45,089 108,700 17,271 Deferred revenue, non-current portion 45,089 108,700 17,271 Deferred revenue, non-current portion 5,325 2,889 364 Lease deposits 5,100 3,535 2,995 Deferred revenue, on-current portion				
Accumis payable 10.332 2,170 345 Accuma for purchase of property, plant and equipment 10,404 13,294 2,115 Obligations under capital leases, current portion 3,582 3,582 369 Accrued expenses and other liabilities 49,935 59,097 9,390 Income tax payable 25,401 20,936 3,266 Deferred revenue, current portion 14,072 11,999 1,906 Total current liabilities 269,152 216,72 34,255 Won-current liabilities 45,089 108,700 17,271 Defered revenue, current portion 45,089 108,700 17,271 Defered revenue, non-current portion 45,089 108,700 17,271 Defered revenue, non-current portion 5,032 2,899 34 Designations under capitalized leases, non-current portion 5,132 2,899 34 Lease deposits 5,132 2,899 34 2,895 Total liabilities 36,102 35,530 2,505 104 10 2,005 10	Short-term bank borrowings	83,000	15,000	2,383
Accumis payable 10.332 2,170 345 Accuma for purchase of property, plant and equipment 10,404 13,294 2,115 Obligations under capital leases, current portion 3,582 3,582 369 Accrued expenses and other liabilities 49,935 59,097 9,390 Income tax payable 25,401 20,936 3,266 Deferred revenue, current portion 14,072 11,999 1,906 Total current liabilities 269,152 216,72 34,255 Won-current liabilities 45,089 108,700 17,271 Defered revenue, current portion 45,089 108,700 17,271 Defered revenue, non-current portion 45,089 108,700 17,271 Defered revenue, non-current portion 5,032 2,899 34 Designations under capitalized leases, non-current portion 5,132 2,899 34 Lease deposits 5,132 2,899 34 2,895 Total liabilities 36,102 35,530 2,505 104 10 2,005 10	Long-term bank borrowings, current portion	60,906	77,479	12,310
Accrual for purchase of property, plant and equipment 10,404 13,294 2,112 Obligations under capital leases, current portion 3,582 3,582 569 Accrued expenses and other liabilities 49,935 59,097 9,390 Income tax payable 25,401 20,332 3,262 Deferred revenue, current portion 11,520 13,155 2,084 Contingent business acquisition consideration 14,072 11,992 34,025 Total current liabilities 269,152 216,672 34,255 Non-current liabilities 45,089 108,70 17,271 Deferred revenue, non-current portion 9,081 6,839 11,872 Obligations under capitalized leases, non-current portion 9,081 6,839 1,872 Deferred avenue, non-current portion 5,325 2,289 364 Lease deposits 5,110 2,000 318 Deferred revenue, non-current portion 9,081 6,839 1,935 Total inabilities non-current portion 9,081 2,005 1,005 Total inabilities non-c		10,332		345
Accrued expenses and other liabilities 49,935 59,097 9,300 Income tax payable 25,401 20,936 3,26 Deferred revenue, current portion 11,520 13,115 2,804 Contingent business acquisition consideration 14,072 11,999 1,905 Total current liabilities 269,152 216,672 34,225 Non-current liabilities 845,089 108,700 17,271 Deferred revenue, non-current portion 9,081 6,839 1,087 Obligations under capitalized leases, non-current portion 9,081 6,839 1,087 Deferred tax liabilities, non-current portion 27,452 1,865 2,995 Total non-current liabilities 29,057 136,678 22,035 Total liabilities 361,209 355,350 56,460 Commitments and contingencies 29,057 136,678 22,035 Total liabilities 361,209 355,350 56,460 Commitments and contringencies 9 10 1 Tereasuary stock 9 1 <td< td=""><td></td><td>10,404</td><td>13,294</td><td>2,112</td></td<>		10,404	13,294	2,112
Accrued expenses and other liabilities 49,935 59,097 9,300 Income tax payable 25,401 20,936 3,26 Deferred revenue, current portion 11,520 13,115 2,804 Contingent business acquisition consideration 14,072 11,999 1,905 Total current liabilities 269,152 216,672 34,225 Non-current liabilities 845,089 108,700 17,271 Deferred revenue, non-current portion 9,081 6,839 1,087 Obligations under capitalized leases, non-current portion 9,081 6,839 1,087 Deferred tax liabilities, non-current portion 27,452 1,865 2,995 Total non-current liabilities 29,057 136,678 22,035 Total liabilities 361,209 355,350 56,460 Commitments and contingencies 29,057 136,678 22,035 Total liabilities 361,209 355,350 56,460 Commitments and contringencies 9 10 1 Tereasuary stock 9 1 <td< td=""><td></td><td>3,582</td><td></td><td>569</td></td<>		3,582		569
Income tax payable 25,401 20,936 3,26 Deferred revenue, current portion 11,520 13,115 2,084 Contingent business acquisition consideration 14,072 11,999 1,906 Total current liabilities 269,152 216,672 34,425 Non-current liabilities 8,081 108,700 17,271 Deferred revenue, non-current portion 9,081 6,839 1,087 Defigations under capitalized leases, non-current portion 5,325 2,289 364 Lease deposits 5,110 2,000 318 Deferred tax liabilities, non-current portion 27,452 18,850 2,995 Total Inor-current liabilities 361,209 355,350 56,460 Commitment 27,452 18,850 2,905 Total liabilities 361,209 355,350 56,460 Commitment 2,005 51,04 17 Teasuary shares 105 104 17 Teasuary stock - 1 - Accumulated other comprehensive loss <td></td> <td>49,935</td> <td>59,097</td> <td>9,390</td>		49,935	59,097	9,390
Contingent business acquisition consideration 14,072 11,999 1,906 Tota current liabilities 269,152 216,672 34,252 Non-current liabilities 8 10,870 17,271 Long-term bank borrowings, non-current portion 45,089 10,870 17,271 Deferred revenue, non-current portion 9,081 6,839 1,087 Obligations under capitalized leases, non-current portion 5,325 2,289 364 Lease deposits 5,110 2,000 318 Deferred tax liabilities, non-current portion 27,452 18,550 2,995 Total non-current liabilities 361,209 35,350 26,905 Total long-turrent liabilities 361,209 35,350 56,400 Total long-turrent liabilities 361,209 35,350 56,400 Total long-turrent liabilities 361,209 35,350 56,400 Committee total 361,209 35,350 56,400 Committee total 10 1 1 Committee total 10 1 1	Income tax payable	25,401	20,936	3,326
Total current liabilities 269,152 216,672 34,455 Non-current liabilities 345,000 108,700 17,271 Long-term bank borrowings, non-current portion 45,000 108,700 17,271 Deferred revenue, non-current portion 9,001 6,839 1,087 Cobligations under capitalized leases, non-current portion 5,110 2,000 318 Lease deposits 5,110 2,000 318 Deferred tax liabilities, non-current portion 27,452 18,500 2,905 Total non-current liabilities 92,057 138,678 22,035 Total liabilities 361,209 353,500 56,400 Commitments and contingencies 361,209 353,500 56,400 Commitments and contingencies 105 104 17 Total graph shares 105 104 17 Total controlling increase 105 104 17 Total controlling increase 105 10,500 2,51,877 405,452 Accumulated other comprehensive loss (14,835) 17,59	Deferred revenue, current portion	11,520	13,115	2,084
Non-current liabilities Section of the properties of the prope	Contingent business acquisition consideration	14,072	11,999	1,906
Long-term bank borrowings, non-current portion 45,089 108,700 17,271 Deferred revenue, non-current portion 9,081 6,839 1,087 Obligations under capitalized leases, non-current portion 5,325 2,289 364 Lease deposits 5,110 2,000 318 Deferred tax liabilities, non-current portion 27,452 18,850 2,995 Total non-current liabilities 361,209 355,350 56,460 Commitments and contingencies EQUITY Ordinary shares 105 104 17 Treasuary stock — 1 — Additional paid-in capital 2,604,704 2,551,877 405,452 Accumulated other comprehensive loss (14,835) (17,596) (2,796) Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,038,096 323,820	Total current liabilities	269,152	216,672	34,425
Deferred revenue, non-current portion 9,081 6,839 1,087 Obligations under capitalized leases, non-current portion 5,325 2,289 364 Lease deposits 5,110 2,000 318 Deferred tax liabilities, non-current portion 27,452 18,850 2,995 Total non-current liabilities 361,209 355,350 56,460 Commitments and contingencies 5 105 104 17 Commitments and contingencies 105 104 17 Treasuary stock - 1 - Additional paid-in capital 2,604,704 2,551,877 405,452 Accumulated other comprehensive loss (14,835) (17,596) (2,796) Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Total equity 2,301,835 2,038,096 323,820	Non-current liabilities			
Deferred revenue, non-current portion 9,081 6,839 1,087 Obligations under capitalized leases, non-current portion 5,325 2,289 364 Lease deposits 5,110 2,000 318 Deferred tax liabilities, non-current portion 27,452 18,850 2,995 Total non-current liabilities 361,209 355,350 56,460 Commitments and contingencies 5 105 104 17 Commitments and contingencies 105 104 17 Treasuary stock - 1 - Additional paid-in capital 2,604,704 2,551,877 405,452 Accumulated other comprehensive loss (14,835) (17,596) (2,796) Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Total equity 2,301,835 2,038,096 323,820	Long-term bank borrowings, non-current portion	45,089	108,700	17,271
Lease deposits 5,110 2,000 318 Deferred tax liabilities, non-current portion 27,452 18,850 2,995 Total non-current liabilities 92,057 138,678 22,035 Total liabilities 361,209 355,350 56,460 Commitments and contingencies EQUITY Ordinary shares 105 104 17 Treasuary stock — 1 — Additional paid-in capital 2,604,704 2,551,877 405,452 Accumulated other comprehensive loss (14,835) (17,596) (2,796) Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,038,096 323,820	Deferred revenue, non-current portion	9,081	6,839	1,087
Lease deposits 5,110 2,000 318 Deferred tax liabilities, non-current portion 27,452 18,850 2,995 Total non-current liabilities 92,057 138,678 22,035 Total liabilities 361,209 355,350 56,460 Commitments and contingencies EQUITY Ordinary shares 105 104 17 Treasuary stock — 1 — Additional paid-in capital 2,604,704 2,551,877 405,452 Accumulated other comprehensive loss (14,835) (17,596) (2,796) Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,038,096 323,820		5,325		364
Total non-current liabilities 92,057 138,678 22,035 Total liabilities 361,209 355,350 56,460 Commitments and contingencies EQUITY Ordinary shares 105 104 17 Treasuary stock — 1 — Additional paid-in capital 2,604,704 2,551,877 405,452 Accumulated other comprehensive loss (14,835) (17,596) (2,796) Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,08,096 323,820	Lease deposits			318
Total liabilities 361,209 355,350 56,460 Commitments and contingencies EQUITY Ordinary shares 105 104 17 Treasuary stock — 1 — Additional paid-in capital 2,604,704 2,551,877 405,452 Accumulated other comprehensive loss (14,835) (17,596) (2,796) Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,038,096 323,820	Deferred tax liabilities, non-current portion	27,452	18,850	2,995
Total liabilities 361,209 355,350 56,460 Commitments and contingencies EQUITY Ordinary shares 105 104 17 Treasuary stock — 1 — Additional paid-in capital 2,604,704 2,551,877 405,452 Accumulated other comprehensive loss (14,835) (17,596) (2,796) Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,038,096 323,820	Total non-current liabilities	92,057	138,678	22,035
Commitments and contingencies EQUITY Ordinary shares 105 104 17 Treasuary stock — 1 — Additional paid-in capital 2,604,704 2,551,877 405,452 Accumulated other comprehensive loss (14,835) (17,596) (2,796) Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,038,096 323,820				
EQUITY Ordinary shares 105 104 17 Treasuary stock — 1 — Additional paid-in capital 2,604,704 2,551,877 405,452 Accumulated other comprehensive loss (14,835) (17,596) (2,796) Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,038,096 323,820				
Ordinary shares 105 104 17 Treasuary stock — 1 — Additional paid-in capital 2,604,704 2,551,877 405,452 Accumulated other comprehensive loss (14,835) (17,596) (2,796) Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,038,096 323,820	-			
Treasuary stock — 1 — Additional paid-in capital 2,604,704 2,551,877 405,452 Accumulated other comprehensive loss (14,835) (17,596) (2,796) Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,038,096 323,820		105	104	17
Additional paid-in capital 2,604,704 2,551,877 405,452 Accumulated other comprehensive loss (14,835) (17,596) (2,796) Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,038,096 323,820		103		1/
Accumulated other comprehensive loss (14,835) (17,596) (2,796) Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,038,096 323,820	-			405.452
Accumulated deficit (384,883) (599,886) (95,313) Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,038,096 323,820				
Total Concord Medical Services Holdings Limited shareholders' equity 2,205,091 1,934,500 307,360 Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,038,096 323,820	-			
Non-controlling interests 96,744 103,596 16,460 Total equity 2,301,835 2,038,096 323,820				
Total equity 2,301,835 2,038,096 323,820				
Total liabilities and equity 2,663,044 2,393,446 380,280				
	Total liabilities and equity	2,663,044	2,393,446	380,280

^(*) Amounts for the year ended December 31, 2010 were derived from the December 31, 2010 audited consolidated financial statements.

Concord Medical Services Holdings Limited Unaudited Condensed Consolidated Statements of Income (in thousands, except per ADS data)

		e Three Months E		For The Twelve Months Ended		
	December 31, 2010 (*)			December 31, December 31 2010 (*) 2011		
	RMB	RMB	US\$	RMB	RMB	US\$
Revenues, net of business tax, value-added tax and related						
surcharges						
Lease and management services	80,002	88,596	14,076	349,248	380,457	60,449
management service	22,805	10,578	1,681	22,805	33,584	5,336
Others, Net	10,056	14,975	2,379	17,471	36,084	5,733
Total net revenues	112,863	114,149	18,136	389,524	450,125	71,518
Cost of revenues						
Depreciation	(21,592)	(25,030)	(3,977)	(79,650)	(93,079)	(14,789)
Amortization of acquired intangibles	(5,333)	(6,287)	(999)	(26,488)	(25,058)	(3,981)
Others	(4,410)	(13,458)	(2,138)	(16,562)	(41,279)	(6,559)
Total cost of revenues	(31,335)	(44,775)	(7,114)	(122,700)	(159,416)	(25,329)
Gross profit	81,528	69,374	11,022	266,824	290,709	46,189
Operating expenses						
Selling expenses	(8,555)	(13,836)	(2,198)	(17,150)	(37,453)	(5,951)
General and administrative expenses	(21,534)	(64,468)	(10,243)	(70,008)	(114,399)	(18,176)
Operating income/(loss)	51,439	(8,930)	(1,419)	179,666	138,857	22,062
Interest expenses	(1,226)	(2,002)	(318)	(7,448)	(6,454)	(1,025)
Goodwill impairment loss	_	(300,163)	(47,691)	_	(300,163)	(47,691)
Foreign exchange loss	(671)	(1,017)	(162)	(5,436)	(10,975)	(1,744)
Gain from disposal of property, plant and equipment	_	_	_	543	_	_
Interest income	4,672	8,030	1,276	7,865	13,357	2,121
Other expenses	(399)	864	137	(399)	346	56
Income/(loss) before income taxes	53,815	(303,218)	(48,177)	174,791	(165,032)	(26,221)
Income tax expenses	(10,137)	(6,790)	(1,079)	(43,873)	(46,320)	(7,360)
Net income/(loss)	43,678	(310,008)	(49,256)	130,918	(211,352)	(33,581)
Net loss attributable to noncontrolling interests	(1,521)	(394)	(63)	(1,518)	(3,651)	(580)
Net income/(loss) attributable to ordinary shareholders	42,157	(310,402)	(49,319)	129,400	(215,003)	(34,161)
Earnings per ADS						
Basic /Diluted	0.87	(6.56)	(1.04)	2.66	(4.53)	(0.72)
Weighted average number of ADS outstanding:						
Basic /Diluted	48,628,990	47,316,183	47,316,183	48,680,198	47,417,151	47,417,151

^(*) Certain amounts in the prior year quarterly financial information are being reclassified for comparison purposes.

Reconciliations of non-GAAP results of operations measures to the nearest comparable GAAP measures (*) (in RMB thousands, unaudited)

	For the three months ended		For the three months ended		Twelve months ended		Twelve months ended		led			
	December 31, 2010			December 31, 2011			December 31, 2010			December 31, 2011		
			Non-			Non-			Non-			Non-
	GAAP		GAAP	GAAP		GAAP	GAAP		GAAP	GAAP		GAAP
	Measure	Adjustment	Measure	Measure	Adjustment	Measure	Measure	Adjustment	Measure	Measure	Adjustment	Measure
Operating income/(loss)	51,439	4,320	55,759	(8,930)	51,531	42,601	179,666	12,083	191,749	138,857	58,502	197,359
Net income/(loss)	43,678	4,320	47,998	(310,008)	351,694	41,686	130,918	12,083	143,001	(211,352)	358,665	147,313
Basic earnings per ADS	0.87	0.09	0.96	(6.56)	7.43	0.87	2.66	0.25	2.91	(4.53)	7.56	3.03
Diluted earnings per ADS	0.87	0.09	0.96	(6.56)	7.43	0.87	2.66	0.25	2.91	(4.53)	7.56	3.03

*) The adjustment is share-based compensation, bad debt provision, other asset loss impairment (excluding tax impact) and goodwill impairment loss.

Reconciliation from net income to adjusted EBITDA(*) (in RMB thousands, unaudited)

Not in constant	For the three months ended December 31, 2010	For the three months ended December 31, 2011	For the twelve months ended December 31, 2010	For the twelve months ended December 31,
Net income/(loss)	43,678	(310,008)	130,918	(211,352)
Interest expenses, net	(3,446)	(6,028)	(417)	(6,903)
Income tax expenses	10,137	6,790	43,873	46,320
Depreciation and amortization	27,400	32,200	106,138	121,049
Share-based compensation	1,807	2,383	9,570	9,234
Bad debt provision	_	15,377	_	15,497
Other impairment loss	2,513	33,771	2,513	33,771
Goodwill impairment loss	_	300,163	_	300,163
Other adjustments	1,070	153	5,292	10,629
Adjusted EBITDA	83,159	74,801	297,887	318,408

^(*) Definition of adjusted EBITDA: Adjusted EBITDA is defined as net income plus interest, taxes, depreciation and amortization, share-based compensation expenses, bad debt provision, fixed asset impairment, goodwill impairment and other adjustments. Other adjustments include foreign exchange loss, gain from disposed of PPE and other income or expense.